Alerce Biologix

Alerce Biologics is a pre-clinical stage biotechnology company headquartered in South San Francisco, California, specializing in the development of next-generation multi-specific antibodies. The company utilizes a proprietary protein engineering platform to create conditional or masked therapeutics designed to activate selectively within the tumor microenvironment. This approach aims to enhance the therapeutic index of potent immune-modulators by minimizing systemic exposure and reducing off-target toxicities. Founded by industry veterans with extensive experience in protein design, Alerce is backed by prominent life science venture capital firms. The company is currently advancing a pipeline of candidates primarily focused on difficult-to-treat solid tumor indications. Alerce represents a new wave of biologics companies focused on precision activation of immune-oncology agents.